

Carol Kruchko Ba

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1058738/publications.pdf>

Version: 2024-02-01

43
papers

11,095
citations

218677

26
h-index

265206

42
g-index

43
all docs

43
docs citations

43
times ranked

13449
citing authors

#	ARTICLE	IF	CITATIONS
1	Importance of the intersection of age and sex to understand variation in incidence and survival for primary malignant gliomas. <i>Neuro-Oncology</i> , 2022, 24, 302-310.	1.2	29
2	A population study of clinical trial accrual for women and minorities in neuro-oncology following the NIH Revitalization Act. <i>Neuro-Oncology</i> , 2022, 24, 1341-1349.	1.2	20
3	Epidemiology of Pineoblastoma in the United States, 2000-2017. <i>Neuro-Oncology Practice</i> , 2022, 9, 149-157.	1.6	4
4	Primary brain and other central nervous system tumors in the United States (2014-2018): A summary of the CBTRUS statistical report for clinicians. <i>Neuro-Oncology Practice</i> , 2022, 9, 165-182.	1.6	40
5	Epidemiology of primary malignant non-osseous spinal tumors in the United States. <i>Spine Journal</i> , 2022, , .	1.3	3
6	Aligning the Central Brain Tumor Registry of the United States (CBTRUS) histology groupings with current definitions. <i>Neuro-Oncology Practice</i> , 2022, 9, 317-327.	1.6	3
7	Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United States. <i>Neuro-Oncology</i> , 2022, 24, 1989-2000.	1.2	27
8	Epidemiology of brainstem high-grade gliomas in children and adolescents in the United States, 2000-2017. <i>Neuro-Oncology</i> , 2021, 23, 990-998.	1.2	28
9	Brain and other central nervous system tumor statistics, 2021. <i>Ca-A Cancer Journal for Clinicians</i> , 2021, 71, 381-406.	329.8	404
10	Impact of race on care, readmissions, and survival for patients with glioblastoma: an analysis of the National Cancer Database. <i>Neuro-Oncology Advances</i> , 2021, 3, vda040.	0.7	7
11	An updated histology recode for the analysis of primary malignant and nonmalignant brain and other central nervous system tumors in the Surveillance, Epidemiology, and End Results Program. <i>Neuro-Oncology Advances</i> , 2021, 3, vdaa175.	0.7	14
12	CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014â€“2018. <i>Neuro-Oncology</i> , 2021, 23, iii1-iii105.	1.2	804
13	The brain tumor not-for-profit and charity experience of COVID-19: reacting and adjusting to an unprecedented global pandemic in the 21st century. <i>Neuro-Oncology Advances</i> , 2021, 3, vdaa166.	0.7	6
14	Association between urbanicity and surgical treatment among patients with primary glioblastoma in the United States. <i>Neuro-Oncology Practice</i> , 2020, 7, 299-305.	1.6	3
15	Brain tumors and COVID-19: the patient and caregiver experience*. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa104.	0.7	17
16	CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013â€“2017. <i>Neuro-Oncology</i> , 2020, 22, iv1-iv96.	1.2	1,175
17	Sex Differences in Cancer Incidence and Survival: A Pan-Cancer Analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1389-1397.	2.5	82
18	Pilocytic astrocytoma: Where do they belong in cancer reporting?. <i>Neuro-Oncology</i> , 2019, 22, 298-300.	1.2	11

#	ARTICLE	IF	CITATIONS
19	CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012–2016. <i>Neuro-Oncology</i> , 2019, 21, v1-v100.	1.2	1,735
20	Cancer collection efforts in the United States provide clinically relevant data on all primary brain and other CNS tumors. <i>Neuro-Oncology Practice</i> , 2019, 6, 330-339.	1.6	17
21	Glioma incidence and survival variations by county-level socioeconomic measures. <i>Cancer</i> , 2019, 125, 3390-3400.	4.1	68
22	Sex is an important prognostic factor for glioblastoma but not for nonglioblastoma. <i>Neuro-Oncology Practice</i> , 2019, 6, 451-462.	1.6	36
23	Racial/ethnic differences in survival for patients with gliosarcoma: an analysis of the National cancer database. <i>Journal of Neuro-Oncology</i> , 2019, 143, 349-357.	2.9	6
24	Nonmalignant and malignant meningioma incidence and survival in the elderly, 2005–2015, using the Central Brain Tumor Registry of the United States. <i>Neuro-Oncology</i> , 2019, 21, 380-391.	1.2	59
25	The CBTRUS story: providing accurate population-based statistics on brain and other central nervous system tumors for everyone. <i>Neuro-Oncology</i> , 2018, 20, 295-298.	1.2	46
26	The elderly left behind—changes in survival trends of primary central nervous system lymphoma over the past 4 decades. <i>Neuro-Oncology</i> , 2018, 20, 687-694.	1.2	159
27	CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011–2015. <i>Neuro-Oncology</i> , 2018, 20, iv1-iv86.	1.2	1,624
28	Survivorship in adults with malignant brain and other central nervous system tumor from 2000–2014. <i>Neuro-Oncology</i> , 2018, 20, vii6-vii16.	1.2	76
29	Adult Glioma Incidence and Survival by Race or Ethnicity in the United States From 2000 to 2014. <i>JAMA Oncology</i> , 2018, 4, 1254.	7.1	373
30	Complete prevalence of malignant primary brain tumors registry data in the United States compared with other common cancers, 2010. <i>Neuro-Oncology</i> , 2017, 19, now252.	1.2	48
31	Incidence and survival trends in oligodendrogliomas and anaplastic oligodendrogliomas in the United States from 2000 to 2013: a CBTRUS Report. <i>Journal of Neuro-Oncology</i> , 2017, 133, 17-25.	2.9	17
32	Global incidence of malignant brain and other central nervous system tumors by histology, 2003–2007. <i>Neuro-Oncology</i> , 2017, 19, 1553-1564.	1.2	146
33	Incidence and survival trends for medulloblastomas in the United States from 2001 to 2013. <i>Journal of Neuro-Oncology</i> , 2017, 135, 433-441.	2.9	62
34	CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014. <i>Neuro-Oncology</i> , 2017, 19, v1-v88.	1.2	1,236
35	Comparative Brain and Central Nervous System Tumor Incidence and Survival between the United States and Taiwan Based on Population-Based Registry. <i>Frontiers in Public Health</i> , 2016, 4, 151.	2.7	40
36	Years of potential life lost for brain and CNS tumors relative to other cancers in adults in the United States, 2010. <i>Neuro-Oncology</i> , 2016, 18, 70-77.	1.2	90

#	ARTICLE	IF	CITATIONS
37	Alex's Lemonade Stand Foundation Infant and Childhood Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011. Neuro-Oncology, 2015, 16, x1-x36.	1.2	414
38	Descriptive epidemiology of World Health Organization grades II and III intracranial meningiomas in the United States. Neuro-Oncology, 2015, 17, 1166-1173.	1.2	169
39	CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. Neuro-Oncology, 2015, 17, iv1-iv62.	1.2	1,727
40	The descriptive epidemiology of atypical teratoid/rhabdoid tumors in the United States, 2001-2010. Neuro-Oncology, 2014, 16, 1392-1399.	1.2	100
41	Primary CNS germ cell tumors in Japan and the United States: an analysis of 4 tumor registries. Neuro-Oncology, 2012, 14, 1194-1200.	1.2	129
42	Consensus Conference on Brain Tumor Definition for Registration. Neuro-Oncology, 2002, 4, 134-145.	1.2	40
43	Brain tumour patients and COVID-19 vaccines: results of an international survey. Neuro-Oncology Advances, 0, , .	0.7	1